At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 342 enrolled
Drug / intervention
Selinexor +1 moredrug
Likely dose
Selinexor 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
In Brief
A Phase 3 clinical trial evaluating Selinexor and Placebo for Dedifferentiated Liposarcoma. Completed, enrolled 342 participants across 71 sites in 10 countries.
Detailed Summary
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDedifferentiated Liposarcoma
CountriesBelgium, Canada, France, Germany, Israel, Italy, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartJan 2016
Primary CompletionOct 2020
Study CompletionOct 2021
TodayJul 2026
First PostedNov 17, 2015
Enrollment StartJan 4, 2016
Primary CompletionOct 28, 2020
Study CompletionOct 26, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 10.6 years ago
Interventions
Selinexordrug
Selinexor 60mg
Placebodrug